Dogwood Therapeutics, Inc. (DWTX) intrinsic value & 10-year financials
Dogwood Therapeutics, Inc. (DWTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.22
- Market cap
- $6.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -73.5%
- Free cash flow (FY2025)
- —
DWTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$34.3M | -$7.13 | — | — | -128.1% |
| FY2024 | — | -$12.3M | -$2.50 | — | — | 49.3% |
| FY2023 | — | -$5.3M | -$0.06 | — | — | -95.1% |
| FY2022 | — | -$12.2M | -$0.22 | — | — | -112.2% |
| FY2021 | — | -$16.0M | -$0.38 | — | — | -71.8% |
| FY2020 | — | -$10.3M | -$0.42 | — | — | -83.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Dogwood Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Dogwood Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -73.5% ROIC.
Dogwood Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Dogwood Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.